Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland

Developmental Cell

Volumn 30, Issue 3, 2014, Pages 295-308

  Desgrosellier, Jay S ^a   Lesperance, Jacqueline ^a   Seguin, Laetitia ^a   Gozo, Maricel ^a   Kato, Shumei ^b   Franovic, Aleksandra ^a   Yebra, Mayra ^a   Shattil, Sanford J ^b   Cheresh, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MAMMARY GLANDS, ANIMAL; MICE; PREGNANCY; STEM CELLS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84905715406     PISSN: 15345807     EISSN: 18781551     Source Type: Journal    
DOI: 10.1016/j.devcel.2014.06.005     Document Type: Article

References (57)

1. Ablooglu A.J., Kang J., Petrich B.G., Ginsberg M.H., Shattil S.J. Antithrombotic effects of targeting alphaIIbbeta3 signaling in platelets. Blood 2009, 113:3585-3592.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
3. Arias-Salgado E.G., Lizano S., Sarkar S., Brugge J.S., Ginsberg M.H., Shattil S.J. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc. Natl. Acad. Sci. USA 2003, 100:13298-13302.
4. Asselin-Labat M.L., Shackleton M., Stingl J., Vaillant F., Forrest N.C., Eaves C.J., Visvader J.E., Lindeman G.J. Steroid hormone receptor status of mouse mammary stem cells. J.Natl. Cancer Inst. 2006, 98:1011-1014.
5. Asselin-Labat M.L., Sutherland K.D., Barker H., Thomas R., Shackleton M., Forrest N.C., Hartley L., Robb L., Grosveld F.G., van der Wees J., et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol. 2007, 9:201-209.
6. Asselin-Labat M.L., Vaillant F., Sheridan J.M., Pal B., Wu D., Simpson E.R., Yasuda H., Smyth G.K., Martin T.J., Lindeman G.J., Visvader J.E. Control of mammary stem cell function by steroid hormone signalling. Nature 2010, 465:798-802.
7. Bai L., Rohrschneider L.R. s-SHIP promoter expression marks activated stem cells in developing mouse mammary tissue. Genes Dev. 2010, 24:1882-1892.
8. Bruno R.D., Smith G.H. Functional characterization of stem cell activity in the mouse mammary gland. Stem Cell Rev. 2011, 7:238-247.
9. Chakrabarti R., Hwang J., Andres Blanco M., Wei Y., Lukačišin M., Romano R.A., Smalley K., Liu S., Yang Q., Ibrahim T., et al. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat. Cell Biol. 2012, 14:1212-1222.
10. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
11. Desgrosellier J.S., Barnes L.A., Shields D.J., Huang M., Lau S.K., Prévost N., Tarin D., Shattil S.J., Cheresh D.A. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat. Med. 2009, 15:1163-1169.
12. Evellin S., Galvagni F., Zippo A., Neri F., Orlandini M., Incarnato D., Dettori D., Neubauer S., Kessler H., Wagner E.F., Oliviero S. FOSL1 controls the assembly of endothelial cells into capillary tubes by direct repression of αv and β3 integrin transcription. Mol. Cell. Biol. 2013, 33:1198-1209.
13. Fata J.E., Kong Y.Y., Li J., Sasaki T., Irie-Sasaki J., Moorehead R.A., Elliott R., Scully S., Voura E.B., Lacey D.L., et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
14. Felding-Habermann B., O'Toole T.E., Smith J.W., Fransvea E., Ruggeri Z.M., Ginsberg M.H., Hughes P.E., Pampori N., Shattil S.J., Saven A., Mueller B.M. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA 2001, 98:1853-1858.
15. Feng X.H., Lin X., Derynck R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J. 2000, 19:5178-5193.
16. Galliher A.J., Schiemann W.P. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2006, 8:R42.
17. Gonzalez-Suarez E., Jacob A.P., Jones J., Miller R., Roudier-Meyer M.P., Erwert R., Pinkas J., Branstetter D., Dougall W.C. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
18. Gorska A.E., Jensen R.A., Shyr Y., Aakre M.E., Bhowmick N.A., Moses H.L. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am. J. Pathol. 2003, 163:1539-1549.
19. Guo W., Keckesova Z., Donaher J.L., Shibue T., Tischler V., Reinhardt F., Itzkovitz S., Noske A., Zürrer-Härdi U., Bell G., et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012, 148:1015-1028.
20. Hu Y., Smyth G.K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J.Immunol. Methods 2009, 347:70-78.
21. Jeselsohn R., Brown N.E., Arendt L., Klebba I., Hu M.G., Kuperwasser C., Hinds P.W. Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 2010, 17:65-76.
22. Jhappan C., Geiser A.G., Kordon E.C., Bagheri D., Hennighausen L., Roberts A.B., Smith G.H., Merlino G. Targeting expression of a transforming growth factor beta 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J. 1993, 12:1835-1845.
23. Joshi P.A., Jackson H.W., Beristain A.G., Di Grappa M.A., Mote P.A., Clarke C.L., Stingl J., Waterhouse P.D., Khokha R. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807.
24. Jungert K., Buck A., Buchholz M., Wagner M., Adler G., Gress T.M., Ellenrieder V. Smad-Sp1 complexes mediate TGFbeta-induced earlytranscription of oncogenic Smad7 in pancreatic cancer cells. Carcinogenesis 2006, 27:2392-2401.
25. Katsuno Y., Lamouille S., Derynck R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr. Opin. Oncol. 2013, 25:76-84.
26. Kim J.Y., Kim Y.M., Yang C.H., Cho S.K., Lee J.W., Cho M. Functional regulation of Slug/Snail2 is dependent on GSK-3β-mediated phosphorylation. FEBS J. 2012, 279:2929-2939.
27. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
28. Liapis H., Flath A., Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn. Mol. Pathol. 1996, 5:127-135.
29. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., Asselin-Labat M.L., Gyorki D.E., Ward T., Partanen A., et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009, 15:907-913. kConFab.
30. Lim E., Wu D., Pal B., Bouras T., Asselin-Labat M.L., Vaillant F., Yagita H., Lindeman G.J., Smyth G.K., Visvader J.E. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 2010, 12:R21.
31. Matulka L.A., Triplett A.A., Wagner K.U. Parity-induced mammary epithelial cells are multipotent and express cell surface markers associated with stem cells. Dev. Biol. 2007, 303:29-44.
32. Monks J. TGFbeta as a potential mediator of progesterone action in the mammary gland of pregnancy. J.Mammary Gland Biol. Neoplasia 2007, 12:249-257.
33. Moustakas A., Heldin C.H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007, 98:1512-1520.
34. Munoz R., Man S., Shaked Y., Lee C.R., Wong J., Francia G., Kerbel R.S. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006, 66:3386-3391.
35. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., Bernard L., Viale G., Pelicci P.G., Di Fiore P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
36. Poncelet A.C., Schnaper H.W. Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. J.Biol. Chem. 2001, 276:6983-6992.
37. Proia T.A., Keller P.J., Gupta P.B., Klebba I., Jones A.D., Sedic M., Gilmore H., Tung N., Naber S.P., Schnitt S., et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011, 8:149-163.
38. Raney B.J., Cline M.S., Rosenbloom K.R., Dreszer T.R., Learned K., Barber G.P., Meyer L.R., Sloan C.A., Malladi V.S., Roskin K.M., et al. ENCODE whole-genome data in the UCSC genome browser (2011 update). Nucleic Acids Res. 2011, 39:D871-D875.
39. Robinson S.D., Silberstein G.B., Roberts A.B., Flanders K.C., Daniel C.W. Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development. Development 1991, 113:867-878.
40. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat. Rev. Cancer 2006, 6:281-291.
41. Schramek D., Leibbrandt A., Sigl V., Kenner L., Pospisilik J.A., Lee H.J., Hanada R., Joshi P.A., Aliprantis A., Glimcher L., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
42. Seguin L., Kato S., Franovic A., Camargo M.F., Lesperance J., Elliott K.C., Yebra M., Mielgo A., Lowy A.M., Husain H., et al. An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 2014, 16:457-468.
43. Shackleton M., Vaillant F., Simpson K.J., Stingl J., Smyth G.K., Asselin-Labat M.L., Wu L., Lindeman G.J., Visvader J.E. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88.
44. Sloan E.K., Pouliot N., Stanley K.L., Chia J., Moseley J.M., Hards D.K., Anderson R.L. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006, 8:R20.
45. Smith G.H., Medina D. Re-evaluation of mammary stem cell biology based on invivo transplantation. Breast Cancer Res. 2008, 10:203.
46. Spike B.T., Engle D.D., Lin J.C., Cheung S.K., La J., Wahl G.M. A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell 2012, 10:183-197.
47. Stingl J. Detection and analysis of mammary gland stem cells. J.Pathol. 2009, 217:229-241.
48. Stingl J., Eirew P., Ricketson I., Shackleton M., Vaillant F., Choi D., Li H.I., Eaves C.J. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
49. Taddei I., Deugnier M.A., Faraldo M.M., Petit V., Bouvard D., Medina D., Fässler R., Thiery J.P., Glukhova M.A. Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat. Cell Biol. 2008, 10:716-722.
50. Takayama S., Ishii S., Ikeda T., Masamura S., Doi M., Kitajima M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res. 2005, 25(1A):79-83.
51. Taverna D., Crowley D., Connolly M., Bronson R.T., Hynes R.O. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res. 2005, 65:10324-10329.
52. Vaillant F., Asselin-Labat M.L., Shackleton M., Forrest N.C., Lindeman G.J., Visvader J.E. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 2008, 68:7711-7717.
53. van Amerongen R., Bowman A.N., Nusse R. Developmental stage and time dictate the fate of Wnt/β-catenin-responsive stem cells in the mammary gland. Cell Stem Cell 2012, 11:387-400.
54. Van Keymeulen A., Rocha A.S., Ousset M., Beck B., Bouvencourt G., Rock J., Sharma N., Dekoninck S., Blanpain C. Distinct stem cells contribute to mammary gland development and maintenance. Nature 2011, 479:189-193.
55. Visvader J.E. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009, 23:2563-2577.
56. Wagner K.U., Boulanger C.A., Henry M.D., Sgagias M., Hennighausen L., Smith G.H. An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development 2002, 129:1377-1386.
57. Wu Z.Q., Li X.Y., Hu C.Y., Ford M., Kleer C.G., Weiss S.J. Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc. Natl. Acad. Sci. USA 2012, 109:16654-16659.